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FDA Updates – Initiatives, Programs, and 
Databases
Did you know that Food and Drug Administration (FDA) writes and 
films videos just for you? The team of pharmacists at FDA’s Division of 
Drug Information wants their fellow pharmacists to have quick, easy 
access to information about FDA initiatives, programs, and databases. 
Last October, the agency announced the release of its brand new videos 
in the Drug Info Rounds series, and the Iowa Board of Pharmacy would 
like to remind you of these important videos.
The first video in FDA’s new series is Medication Adherence. In less 
than three minutes, FDA pharmacists share tips and tools to help you and 
your patients better communicate about safe medication use, including:
 ♦ For you: www.scriptyourfuture.org offers wallet cards, posters, 
door hangers, and more for you to use in your pharmacy.
 ♦ For your patients: Stop – Learn – Go – Tips for Talking with 
Your Pharmacist
Other videos in the series include Breakthrough Therapy, Antibiotic 
Resistance, and MedWatch Tips & Tools (tutorial).
The most popular videos from previous seasons include Accelerated 
Approval Program, Medication Errors, Disposal of Unused Medicines, 
and Electronic Orange Book.
Watch the videos online at http://go.usa.gov/ccfuh. 
Annual CS Inventories: What to Include?
By Jean Rhodes, RPh, Board Compliance Officer
An annual controlled substance (CS) inventory is required to be 
taken on any date that is within one year plus seven days after the date 
of the previous annual inventory. The date and time of day (open or 
close of business) and the signature of the person(s) completing the 
inventory must be on the inventory record. This task can be delegated, 
and technicians or pharmacists may complete the inventory record. 
The inventory must account for all CS under the registrant’s control. 
This includes any expired medications, filled prescriptions waiting to 
be picked up, and drugs in automated dispensing systems or emergency 
kits that are owned by the pharmacy, including emergency medical 
service or long-term care emergency kits.
Compounding Convenience Kits
By Sue Mears, MBA, RPh, Board Compliance Officer, and  
Laura Steffensmeier, Iowa Assistant Attorney General
Over the last few years, companies have been increasingly selling 
compounding “convenience kits” containing bulk drug ingredients 
that, when combined in accordance with the instructions, create a 
compounded drug product. Pharmacists have often posed two questions 
regarding these kits. First, if a convenience kit is commercially avail-
able, do they have to use it to compound the product? The answer is no; 
a pharmacy is not required to utilize a convenience kit to compound a 
drug product. A convenience kit is considered a bulk drug ingredient 
for human prescription compounding by FDA. Convenience kits, on 
their own, are not considered FDA-approved products (even though 
they may be labeled with a National Drug Code number), nor are they 
considered “finished pharmaceuticals.” A pharmacy is not required 
to utilize a convenience kit to compound a drug product for a patient. 
Second, does the pharmacist still need to complete and maintain a 
compounding record when making a compounded drug product using 
a convenience kit? The answer is yes; a pharmacy is still required to 
complete a compounding record when compounding a drug product 
using a convenience kit. Because the kit itself is not an FDA-approved 
product, following the kit’s instructions is not considered mixing or 
reconstituting per the manufacturer label, and is therefore not exempt 
from the definition of compounding and not exempt from the record-
keeping requirements applicable to all compounded drug products.
Can Technicians Perform Drug Identification?
By Terry Witkowski, Board Executive Officer
The identification of medication may be performed by a pharmacy 
technician as long as the pharmacist-in-charge and the supervising 
pharmacist agree to permit the technician to perform that function. 
Policies and procedures should clearly define who can perform the 
function, when the pharmacist should be consulted (eg, if the technician 
cannot clearly identify the medication or has questions), the resources 
to be used to assist in identifying the medication, and the limits of the 
technician’s interaction with the practitioner. For example, the techni-
cian may identify the medication to the practitioner but should not advise 
the practitioner regarding the advisability of the patient’s continued use 
of the medication or the implied diagnosis that prompted the patient’s 
need or use of the medication. 
Commonly Found Deficiencies: Vaccine 
Administration
By Jean Rhodes, RPh, Board Compliance Officer
During any pharmacist renewal period, an authorized pharmacist 
who engages in the administration of vaccines shall complete and 
document at least one hour of continuing education (CE) related to 
vaccines. Please maintain documentation or proof of the following 
in the pharmacy in which you are administering vaccines: current 
CPR certification, vaccine administration training, and verification of 
completion of one CE unit pertaining to the administration of vaccines 
per pharmacist license renewal cycle.
The pharmacy must have the emergency medications and supplies 
listed in the protocol. During recent inspections, several pharmacies 
have not had the listed amount of epinephrine doses for children. 
Continued on page 4
FDA-approved for use in combination with each other or for 
topical use. Patients are charged per ingredient, with many 
creams containing numerous, expensive medications. Toxicity 
from the creams has been reported to poison control centers, 
including cases of accidental child exposures and intentional 
use for multiple family members. Patients are often unaware 
of the dangers with using the creams, which include unsafe 
packaging in containers without child-resistant closures. 
ISMP is specifically concerned about some statements that 
may be unproven, such as the products’ safe use with chil-
dren. Compounded pain creams need prominent warnings on 
labels that describe the potential for toxicity, and physicians 
and pharmacists who prescribe and dispense the creams must 
provide patients with instructions about possible adverse ef-
fects, safe storage, and proper use. ISMP believes regulatory 
or licensing oversight is necessary.
7) Clear Care: Still Causing Severe Eye Injuries Five
Years Later
Since early 2010, ISMP has received scores of reports
of painful eye injuries from patients using CLEAR CARE® 
Cleaning & Disinfecting Solution for contact lenses by Alcon 
(formerly CIBA VISION), a Novartis company, and similar 
store-brand products. Hundreds more can be found on Internet 
listservs. Located on store shelves near other lens disinfectants 
and solutions, these disinfecting products differ from other 
commonly used solutions in that they must be used with a 
special lens case in order to neutralize the 3% hydrogen per-
oxide component of the solution over at least six hours before 
putting the lenses back into the eyes. However, many patients 
have inadvertently used the solution to soak their lenses in 
a standard lens case, or thought the solution was saline and 
instilled it directly into their eyes. This has caused severe eye 
burning, leading many to seek out emergency medical care 
for corneal burns. In 2012, Alcon made a label enhancement 
to warn customers to use the special lens case, but the label 
change has been ineffective. Neither the company nor FDA’s 
Medical Devices division have been persuaded to make ef-
fective label improvements before permanent eye injury or 
blindness occurs. If the labeling and packaging cannot be 
improved to reduce the harm being reported, perhaps these 
products should be pulled from the market or available only 
behind the pharmacy counter.
Risk of Dose Confusion and Medication 
Errors With Avycaz, FDA Cautions
Confusion about the drug strength displayed on the vial 
and carton labels has led to some dosing errors with the 
intravenous antibacterial drug Avycaz™ (ceftazidime and 
avibactam), warned FDA in September 2015. The agency 
explained that Avycaz was initially approved with the vial and 
carton labels displaying the individual strengths of the two 
active ingredients (2 g/0.5 g); however, the product is dosed 
based on the sum of the active ingredients (2.5 g). To prevent 
medication errors, FDA revised the labels to indicate that each 
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Discontinue Use of Chen Shwezin Sterile 
Drug Products, FDA Warns
In October 2015, the United States Food and Drug Ad-
ministration (FDA) issued a statement alerting health care 
providers and patients not to use drug products intended to 
be sterile that were made and distributed by Chen Shwezin, 
Inc, dba Park Compounding Pharmacy of Westlake Village, 
CA, because of lack of sterility assurance. Following an FDA 
inspection during which investigators observed unsanitary 
conditions, including poor sterile production practices, FDA 
recommended that Park Compounding Pharmacy cease sterile 
operations and recall all of its non-expired sterile drug prod-
ucts. However, the company had refused to recall its products, 
according to an FDA safety alert.
At this time, FDA has not received reports of any ad-
verse events associated with the use of products from Park 
Compounding Pharmacy. FDA recommends that health care 
providers check their medical supplies, quarantine any sterile 
drug products from Park Compounding Pharmacy, and not 
administer them to patients. 
More information is available in the FDA safety alert, avail-
able at www.fda.gov/Safety/MedWatch/SafetyInformation/ 
SafetyAlertsforHumanMedicalProducts/ucm465582.htm.
Seven Persistent Safety Gaffes in 
Community/Ambulatory Settings That 
Need to Be Resolved!
This column was prepared by the 
Institute for Safe Medication Practices 
(ISMP). ISMP is an independent nonprofit 
agency and federally certified patient safety organization 
that analyzes medication errors, near misses, and potentially 
hazardous conditions as reported by pharmacists and other 
practitioners. ISMP then makes appropriate contacts with 
companies and regulators, gathers expert opinion about 
prevention measures, and publishes its recommendations. To 
read about the risk reduction strategies that you can put into 
practice today, subscribe to ISMP Medication Safety Alert!® 
Community/Ambulatory Care Edition by visiting www.ismp 
.org. ISMP provides legal protection and confidentiality for 
submitted patient safety data and error reports. Help others by 
reporting actual and potential medication errors to the ISMP 
National Medication Errors Reporting Program Report online 
at www.ismp.org. Email: ismpinfo@ismp.org.
This is the final article of a three-part series on seven per-
sistent safety gaffes of 2014.
6) Compounded Pain Creams: High Profit Margin and
Danger
Some compounding pharmacies have been heavily mar-
keting compounded pain creams directly to consumers via 
unsolicited calls, suggesting that the creams are more effective 
and safer than oral or injectable pain medications. Many of the 
creams contain drugs that can cause central nervous system 
depression or adverse cardiac effects, and most have not been 
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vial contains Avycaz 2.5 g, equivalent to ceftazidime 2 g and 
avibactam 0.5 g, according to an FDA safety alert.
As of September 2015, FDA had received reports of three 
medication error cases related to confusion on how the strength 
was displayed on the Avycaz vial and carton labels. Two cases 
stated that the errors occurred during preparation of the dose 
in the pharmacy. The third case described concern about the 
potential for confusion because the strength displayed for 
Avycaz differs from how the strength is displayed for other 
beta-lactam/beta-lactamase drugs. Based on the information 
provided in the reports, FDA is aware that at least one of the 
patients received a higher-than-intended dose of Avycaz. As 
of September 2015, no adverse events were reported. 
More details are included in the FDA safety alert, available 
at www.fda.gov/Safety/MedWatch/SafetyInformation/Safety 
AlertsforHumanMedicalProducts/ucm463595.htm.
US Compounding, Inc, Recalls All Lots of 
Sterile Compounded Products 
In September 2015, US Compounding, Inc, of Conway, AR, 
issued a voluntary recall of all lots of sterile products asepti-
cally compounded and packaged by the company, and that 
remain within expiry, because of a lack of sterility assurance. 
The affected sterile products were distributed nationwide to 
patients, providers, hospitals, and clinics between March 14, 
2015, and September 9, 2015. The recall does not apply to 
any nonsterile compounded medications prepared by US 
Compounding. Providers are advised to discontinue use of 
the products, quarantine any unused product, and contact 
US Compounding to arrange the return of any unused sterile 
compounded products using the information provided in the 
FDA press release, available at www.fda.gov/Safety/Recalls/
ucm464071.htm.
The company issued this recall out of an abundance of 
caution. Providers who have dispensed any sterile product 
distributed by US Compounding should contact patients to 
whom product was dispensed and notify them of this recall. A 
list of all sterile compounded products that have been recalled 
is provided on FDA’s website at www.fda.gov/Safety/Recalls/
ucm464072.htm.
FDA Investigates the Risks of Using Pain 
Medicine Tramadol in Young Patients
As of September 2015, FDA is investigating the use of the 
pain medicine tramadol in young patients because of the rare 
but serious risk of slowed or difficult breathing. This risk may 
be increased in patients treated with tramadol for pain after sur-
gery to remove their tonsils and/or adenoids. Tramadol is not 
FDA-approved for use in patients aged 17 years or younger; 
however, data show it is being used “off-label” in the pediatric 
population, according to the safety alert on FDA’s website, 
available at www.fda.gov/Safety/MedWatch/SafetyInformation/ 
SafetyAlertsforHumanMedicalProducts/ucm463499.htm.
FDA is evaluating all available information and will com-
municate final conclusions and recommendations to the public 
when the review is complete. Health care providers are en-
couraged to report adverse events or side effects related to the 
use of these products to FDA’s MedWatch Safety Information 
and Adverse Event Reporting Program.
Decreased Potency Reported in Drugs 
Stored in Becton-Dickinson Syringes
In September 2015, FDA expanded its alert regarding 
compounded or repackaged drugs stored in Becton-Dickinson 
(BD) general use syringes to include certain additional syringe 
sizes including 1 mL, 10 mL, 20 mL, and 30 mL BD syringes, 
and BD oral syringes. FDA’s original alert applied to com-
pounded or repackaged drugs that have been stored in 3 mL 
and 5 mL BD syringes. The agency expanded the alert based 
on BD reports that an interaction with the rubber stopper in 
certain lots of these syringes can cause some drugs stored in 
these syringes to lose potency if filled and not used immedi-
ately. BD reports that the following drugs in particular can be 
affected by the stoppers, but it does not know whether other 
drugs can be affected: fentanyl, rocuronium, neostigmine, 
morphine, midazolam, methadone, atropine, hydromorphone, 
cisatracurium, and remifentanil. This safety alert does not 
pertain to BD prefilled, prefillable, heparin flush, saline flush, 
or insulin syringes, indicates BD in an alert notice. Further, 
BD’s alert notice also has a search tool to assist customers in 
determining if their lots are affected. FDA advises hospital 
pharmacies and staff to contact any outsourcers to determine 
if affected lots of BD syringes were used for compounded or 
repackaged products. Hospital pharmacies and staff should 
not administer compounded or repackaged drugs that have 
been stored in any of these syringes unless there is no suit-
able alternative available. Adverse reactions may be reported 
to FDA’s MedWatch Safety Information and Adverse Event 
Reporting program. 
More details are included in the FDA Safety Alert, available 
at www.fda.gov/Drugs/DrugSafety/ucm458952.htm.
MediStat Pharmacy Issues Recall of 
Sterile Drug Products
MediStat Pharmacy, a 503B outsourcing facility in Foley, 
AL, has initiated a national recall of all sterile injectable prod-
ucts distributed between November 1, 2014, and September 3, 
2015. The recall is based on the identification of various 
pathogens within the compounding environment. Health care 
providers should check their medical supplies, quarantine 
any drug products marketed as sterile from MediStat, and 
not administer them to patients. FDA has received reports of 
several adverse events that are potentially associated with the 
drug products made by MediStat. MediStat voluntarily ceased 
sterile compounding operations in September 2015. FDA asks 
health care providers and patients to report adverse reactions 
or quality problems experienced with the use of these products 
to the FDA’s MedWatch Adverse Event Reporting program. 
More details are included in an FDA press release, available 
at www.fda.gov/Safety/Recalls/ucm461939.htm.
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Some have included medications not listed in the protocol, such as 
ammonia inhalants (smelling salts).
Technician Registration Versus Technician 
Certification
Pharmacy technicians must be nationally certified by any National 
Commission for Certifying Agencies-accredited pharmacy technician 
certification program and examination to obtain, maintain, and renew 
registration with the Board as a certified technician. Registrations expire 
on the last day of the technician’s birth month and are renewed on a 
two-year cycle; ie, if a technician’s birth month is January and he or she 
obtains registration in July 2016, that registration would expire the last 
day of January 2018. Technicians must provide proof to the Board that 
they have renewed their national certification prior to renewing their 
registration with the Board. 
Technicians: Please remember that you have two items that must 
be renewed and that those renewal periods may or may not coincide. 
USP <797> Compliance Officer Surveys
The Board has recently amended its rules to incorporate United 
States Pharmacopeia (USP) Chapters <795> and <797> by reference. 
In an effort to ensure all pharmacies are aware of and are abiding by 
this requirement, Board compliance officers have been reaching out to 
pharmacies to schedule surveys of sterile compounding practices. This 
is an educational opportunity for pharmacists and technicians, and the 
Board encourages all sites that perform sterile compounding to complete 
the survey. If you have not had an opportunity for a compliance officer 
to complete a survey at your facility, please reach out to your compliance 
officer to schedule a visit. Contact information for compliance officers 
may be found on the Board’s website at https://pharmacy.iowa.gov.
2015 Iowa PMP: Annual Report
The number of inquiries from pharmacists processed through the 
Iowa Prescription Monitoring Program (PMP) in 2015 increased by 32% 
from 2014. Additionally, requests made by prescribers also increased 
from 2014, by 38%.
The total number of prescriptions dispensed in 2015 increased by 
8%, compared to a 2.6% increase in 2014 and a 0.023% increase in 2013. 
This increase is most likely due to Drug Enforcement Administration’s 
(DEA) scheduling of tramadol from a legend drug to a Schedule IV 
drug, which occurred on August 18, 2014.
Hydrocodone and hydrocodone-containing products accounted 
for 20% (down from 26% in 2014) of all doses dispensed, followed by 
tramadol (15%), alprazolam (9%), oxycodone (8%), lorazepam (6%), 
clonazepam (6%), methylphenidates (5%), zolpidem (4%), diazepam 
(2%), and Vyvanse® (2%). 
Since 2010, the number of individuals obtaining Schedule II and 
III prescriptions from five or more prescribers or pharmacies has been 
reduced by 85%. Likewise, the number of individuals obtaining Sched-
ule II and III prescriptions from 10 or more prescribers or pharmacies 
has been reduced by 99%. The PMP continues to gain registered users. 
Prescriber registrations increased by 15% from 2014, while pharmacist 
registrations increased by 13%. 
The complete annual report is on the Board’s website under PMP.
NABP.net: A Wealth of Information
The National Association of Boards of Pharmacy® (NABP®) 
website, www.nabp.net, is chock-full of useful, relevant pharmacy 
practice information. Want to know how to transfer your license to 
another state? Unsure if a wholesaler is reputable? Need to check the 
status of your CE? All of the answers to these questions, and more, can 
be found on the NABP website. 
NABP provides numerous accreditation programs, including: durable 
medical equipment, prosthetics, orthotics, and supplies (DMEPOS); 
Verified-Accredited Wholesale Distributors® (VAWD®); Verified 
Internet Pharmacy Practice Sites® (VIPPS®); Veterinary-Verified 
Internet Pharmacy Practice Sites® (Vet-VIPPS®); and the NABP 
e-Advertiser ApprovalCM Program. Information pertaining to each of 
these accreditation programs is available at www.nabp.net.
Additionally, NABP provides information on its website pertaining 
to the various examinations and assessments it administers, including 
the North American Pharmacist Licensure Examination® (NAPLEX®) 
and the Multistate Pharmacy Jurisprudence Examination® (MPJE®), 
among others.
Finally, if after perusing the NABP website you are still unable to 
find the answers to your questions, simply click on “Questions? Chat 
Is Available” and you will be connected to an NABP agent who can 
assist you.
Follow the Board on Facebook and Twitter
Continued from page 1
Facebook “Iowa Board of Pharmacy”
w w w.facebook .com/page s / Iowa- Board - o f -
Pharmacy/223126781053672
Twitter “IABoardPharmacy”
https://twitter.com/IABoardPharmacy
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